Niu M - Search Results

1

Plumbagin inhibits growth of gliomas in vivo via suppression of FOXM1 expression.

Niu M, Cai W, Liu H, Chong Y, Hu W, Gao S, Shi Q, Zhou X, Liu X, Yu R. Niu M, et al. J Pharmacol Sci. 2015 Jul;128(3):131-6. doi: 10.1016/j.jphs.2015.06.005. Epub 2015 Jun 25. J Pharmacol Sci. 2015. PMID: 26154848 Free article.

2

Tautomycetin induces apoptosis by inactivating Akt through a PP1-independent signaling pathway in human breast cancer cells.

Niu M, Sun Y, Liu X, Tang L, Qiu R. Niu M, et al. J Pharmacol Sci. 2013;121(1):17-24. doi: 10.1254/jphs.12206fp. Epub 2012 Dec 26. J Pharmacol Sci. 2013. PMID: 23269238 Free article.

3

CRM1 is a direct cellular target of the natural anti-cancer agent plumbagin.

Liu X, Niu M, Xu X, Cai W, Zeng L, Zhou X, Yu R, Xu K. Liu X, et al. Among authors: niu m. J Pharmacol Sci. 2014;124(4):486-93. doi: 10.1254/jphs.13240fp. J Pharmacol Sci. 2014. PMID: 24739265 Free article.

4

Plumbagin induces growth inhibition of human glioma cells by downregulating the expression and activity of FOXM1.

Liu X, Cai W, Niu M, Chong Y, Liu H, Hu W, Wang D, Gao S, Shi Q, Hu J, Zhou X, Yu R. Liu X, et al. Among authors: niu m. J Neurooncol. 2015 Feb;121(3):469-77. doi: 10.1007/s11060-014-1664-2. Epub 2014 Dec 21. J Neurooncol. 2015. PMID: 25528634

5

Piperlongumine selectively suppresses ABC-DLBCL through inhibition of NF-κB p65 subunit nuclear import.

Niu M, Shen Y, Xu X, Yao Y, Fu C, Yan Z, Wu Q, Cao J, Sang W, Zeng L, Li Z, Liu X, Xu K. Niu M, et al. Biochem Biophys Res Commun. 2015 Jul 10;462(4):326-31. doi: 10.1016/j.bbrc.2015.04.136. Epub 2015 May 13. Biochem Biophys Res Commun. 2015. PMID: 25979358

6

Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.

Niu M, Chong Y, Han Y, Liu X. Niu M, et al. Cancer Biol Ther. 2015;16(7):1110-8. doi: 10.1080/15384047.2015.1047569. Epub 2015 May 21. Cancer Biol Ther. 2015. PMID: 25996664 Free PMC article.

7

Piperlongumine is a novel nuclear export inhibitor with potent anticancer activity.

Niu M, Xu X, Shen Y, Yao Y, Qiao J, Zhu F, Zeng L, Liu X, Xu K. Niu M, et al. Chem Biol Interact. 2015 Jul 25;237:66-72. doi: 10.1016/j.cbi.2015.05.016. Epub 2015 May 28. Chem Biol Interact. 2015. PMID: 26026911

8

Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer.

Liu X, Chong Y, Liu H, Han Y, Niu M. Liu X, et al. Among authors: niu m. J Ovarian Res. 2015 Jun 10;8:35. doi: 10.1186/s13048-015-0166-y. J Ovarian Res. 2015. PMID: 26055813 Free PMC article.

9

CRM1 inhibitor S109 suppresses cell proliferation and induces cell cycle arrest in renal cancer cells.

Liu X, Chong Y, Liu H, Han Y, Niu M. Liu X, et al. Among authors: niu m. Korean J Physiol Pharmacol. 2016 Mar;20(2):161-8. doi: 10.4196/kjpp.2016.20.2.161. Epub 2016 Feb 23. Korean J Physiol Pharmacol. 2016. PMID: 26937212 Free PMC article.

10

Plumbagin reduces chronic lymphocytic leukemia cell survival by downregulation of Bcl-2 but upregulation of the Bax protein level.

Fu C, Gong Y, Shi X, Sun Z, Niu M, Sang W, Xu L, Zhu F, Wang Y, Xu K. Fu C, et al. Among authors: niu m. Oncol Rep. 2016 Sep;36(3):1605-11. doi: 10.3892/or.2016.4950. Epub 2016 Jul 19. Oncol Rep. 2016. PMID: 27461100

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,726 results

Search Page

Filters